Genocea Biosciences Signs Exclusive License Agreement with Children's Hospital Boston for Novel Streptococcus Pneumoniae Antigens

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genocea Biosciences, a vaccine discovery and development company, today announced an exclusive worldwide license for developed countries to a portfolio of Streptococcus pneumoniae antigens from Children’s Hospital Boston. PATH and Genocea retain certain co-exclusive rights to the antigens for use in developing countries under their collaboration agreements with Children's Hospital Boston. These antigens were identified through a 2008 research collaboration between Genocea, PATH and Children’s Hospital Boston to develop a protein subunit vaccine. This license grants Genocea the right to develop and commercialize vaccines that incorporate these novel antigens.

Back to news